BSE Live
Dec 26, 16:01Prev. Close
5563.80
Open Price
5563.80
Bid Price (Qty.)
5500.00 (20)
Offer Price (Qty.)
5649.00 (1)
NSE Live
Dec 26, 15:56Prev. Close
5566.00
Open Price
5539.00
Bid Price (Qty.)
0.00 (0)
Offer Price (Qty.)
5535.00 (39)
| Balance Sheet of Alkem Laboratories (in Rs. Cr.) | Mar 10 | Mar 09 | Mar 08 | |
| 12 mths | 12 mths | 12 mths | ||
| EQUITIES AND LIABILITIES | ||||
| SHAREHOLDER'S FUNDS | ||||
| Equity Share Capital | 11.96 | 11.96 | 11.96 | |
| Total Share Capital | 11.96 | 11.96 | 11.96 | |
| Reserves and Surplus | 1,193.37 | 972.79 | 834.48 | |
| Total Reserves and Surplus | 1,193.37 | 972.79 | 834.48 | |
| Total Shareholders Funds | 1,205.33 | 984.75 | 846.43 | |
| NON-CURRENT LIABILITIES | ||||
| Long Term Borrowings | 69.55 | 403.28 | 287.62 | |
| Deferred Tax Liabilities [Net] | 30.20 | 31.97 | 25.90 | |
| Other Long Term Liabilities | 0.00 | 0.00 | 0.00 | |
| Long Term Provisions | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Liabilities | 99.75 | 435.25 | 313.52 | |
| CURRENT LIABILITIES | ||||
| Short Term Borrowings | 0.00 | 0.00 | 0.00 | |
| Trade Payables | 0.00 | 0.00 | 0.00 | |
| Other Current Liabilities | 174.41 | 115.01 | 82.75 | |
| Short Term Provisions | 79.86 | 60.24 | 34.45 | |
| Total Current Liabilities | 254.27 | 175.25 | 117.20 | |
| Total Capital And Liabilities | 1,559.34 | 1,595.24 | 1,277.15 | |
| ASSETS | ||||
| NON-CURRENT ASSETS | ||||
| Tangible Assets | 392.17 | 390.01 | 371.77 | |
| Intangible Assets | 0.00 | 0.00 | 0.00 | |
| Capital Work-In-Progress | 8.32 | 6.14 | 13.26 | |
| Other Assets | 0.00 | 0.00 | 0.00 | |
| Fixed Assets | 400.49 | 396.14 | 385.02 | |
| Non-Current Investments | 19.69 | 26.20 | 192.51 | |
| Deferred Tax Assets [Net] | 0.00 | 0.00 | 0.00 | |
| Long Term Loans And Advances | 0.00 | 0.00 | 0.00 | |
| Other Non-Current Assets | 0.00 | 0.00 | 0.00 | |
| Total Non-Current Assets | 420.17 | 422.35 | 577.53 | |
| CURRENT ASSETS | ||||
| Current Investments | 0.00 | 0.00 | 0.00 | |
| Inventories | 175.70 | 195.92 | 205.80 | |
| Trade Receivables | 116.81 | 106.40 | 98.35 | |
| Cash And Cash Equivalents | 661.56 | 727.88 | 300.01 | |
| Short Term Loans And Advances | 185.10 | 142.70 | 95.46 | |
| OtherCurrentAssets | 0.00 | 0.00 | 0.00 | |
| Total Current Assets | 1,139.17 | 1,172.90 | 699.62 | |
| Total Assets | 1,559.34 | 1,595.24 | 1,277.15 | |
| OTHER ADDITIONAL INFORMATION | ||||
| CONTINGENT LIABILITIES, COMMITMENTS | ||||
| Contingent Liabilities | 26.45 | 17.37 | 24.21 | |
| CIF VALUE OF IMPORTS | ||||
| Raw Materials | 30.84 | 26.00 | 20.44 | |
| Stores, Spares And Loose Tools | 0.00 | 0.00 | 0.00 | |
| Trade/Other Goods | 0.00 | 0.00 | 0.00 | |
| Capital Goods | 5.64 | 5.70 | 12.59 | |
| EXPENDITURE IN FOREIGN EXCHANGE | ||||
| Expenditure In Foreign Currency | 17.67 | 10.51 | 3.70 | |
| REMITTANCES IN FOREIGN CURRENCIES FOR DIVIDENDS | ||||
| Dividend Remittance In Foreign Currency | -- | -- | -- | |
| EARNINGS IN FOREIGN EXCHANGE | ||||
| FOB Value Of Goods | 118.58 | 99.85 | 73.51 | |
| Other Earnings | 4.16 | -- | -- | |
| BONUS DETAILS | ||||
| Bonus Equity Share Capital | 8.87 | 8.87 | 8.87 | |
| NON-CURRENT INVESTMENTS | ||||
| Non-Current Investments Quoted Market Value | -- | 1.98 | 1.77 | |
| Non-Current Investments Unquoted Book Value | 1.19 | 25.18 | 191.12 | |
| CURRENT INVESTMENTS | ||||
| Current Investments Quoted Market Value | -- | -- | -- | |
| Current Investments Unquoted Book Value | -- | -- | -- |
04.12.2025
Alkem Lab Consolidated September 2025 Net Sales at Rs 4,000.99 crore, up 17.17% Y-o-Y
24.11.2025
Alkem Lab Standalone September 2025 Net Sales at Rs 2,542.03 crore, down 11.49% Y-o-Y
10.09.2025
Alkem Lab Standalone June 2025 Net Sales at Rs 2,372.17 crore, down 5.12% Y-o-Y
12.08.2025
Q1 Results impact: Alkem Labs, PN Gadgil shares rally up to 10% on strong earnings, Granules up 4%
12.07.2023
Alkem Laboratories Q1 PAT seen up 135.1% YoY to Rs 299.7 cr: Nirmal Bang
17.10.2018
Alkem Labs Q2 PAT may dip 30.2% YoY to Rs. 220 cr: HDFC Securities
20.04.2018
Alkem Labs Q4 PAT may dip 1.5% YoY to Rs. 130 cr: HDFC Securities
12.04.2018
Pharma Q4 earnings preview: Tough quarter; US pricing pressure, domestic sales recovery hold key